ReCode Therapeutics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
105
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$31M
- Investors
-
23
ReCode Therapeutics General Information
Description
Developer of targeted delivery technology designed for patients with rare diseases. The company's platform utilizes lipid nanoparticles to precisely deliver corrective or disease-modifying genetic therapies to specific organs and tissues, potentially overcoming limitations of current gene therapy methods and offering new hope for patients with unmet medical needs, enabling healthcare firms with life-limiting respiratory diseases to avail themselves of medicines.
Contact Information
Website
www.recodetx.comCorporate Office
- 1140 O'Brien Drive
- Menlo Park, CA 94025
- United States
Corporate Office
- 1140 O'Brien Drive
- Menlo Park, CA 94025
- United States
ReCode Therapeutics Timeline
ReCode Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 23-Oct-2025 | $31M | Completed | Clinical Trials - Phase 2 | ||
| 7. Later Stage VC | 18-Nov-2024 | Completed | Clinical Trials - Phase 2 | |||
| 6. Secondary Transaction - Private | Completed | Clinical Trials - Phase 2 | ||||
| 5. Later Stage VC (Series B) | 15-Sep-2023 | Completed | Clinical Trials - Phase 2 | |||
| 4. Secondary Transaction - Private | 27-May-2022 | Completed | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC (Series A1) | 26-Mar-2020 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series A2) | 08-Feb-2019 | $2M | $2M | Completed | Clinical Trials - Phase 2 | |
| 1. University Spin-Out | 01-Jan-2015 | Completed | Clinical Trials - Phase 1 |
ReCode Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A-5 | ||||||||
| Series A-4 | ||||||||
| Series A-3 | ||||||||
| Series A-2 | 1,126,512 | $0.000100 | 5% | $1.85 | $1.85 | 1x | $1.85 | 1.49% |
| Series A-1 | 14,296,176 | $0.000100 | 5% | $5.6 | $5.6 | 1x | $5.6 | 18.86% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
ReCode Therapeutics Comparisons
Industry
Financing
Details
ReCode Therapeutics Competitors (49)
One of ReCode Therapeutics’s 49 competitors is Regenxbio, a Formerly VC-backed company based in Rockville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| Strand Therapeutics | Venture Capital-Backed | Boston, MA | ||||
| ONL Therapeutics | Venture Capital-Backed | Ann Arbor, MI | ||||
| Enterprise Therapeutics | Venture Capital-Backed | Brighton, United Kingdom | ||||
| Aqualung Therapeutics | Venture Capital-Backed | Tucson, AZ |
ReCode Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ReCode Therapeutics Patents
ReCode Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026117699-A1 | Lipid nanoparticle compositions and uses thereof | Pending | 27-Nov-2024 | ||
| WO-2026096988-A1 | Lipid nanoparticle compositions and uses thereof | Pending | 04-Nov-2024 | ||
| WO-2025240355-A1 | Lipid nanoparticles for extrahepatic delivery | Pending | 14-May-2024 | ||
| WO-2025240356-A1 | Lipid nanoparticles for hepatic delivery | Pending | 14-May-2024 | ||
| AU-2025259635-A1 | Systems and methods for generating lipid nanoparticles | Pending | 15-Feb-2024 | B01F23/41 |
ReCode Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ReCode Therapeutics Investors (23)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ABRDN Emerging Markets Equity Income | Asset Manager | |||
| AJU IB Investment | Venture Capital | Minority | ||
| Amgen Ventures | Corporate Venture Capital | Minority | ||
| AyurMaya | Venture Capital | Minority | ||
| Blockchange Ventures | Venture Capital | Minority |
ReCode Therapeutics Acquisitions (1)
ReCode Therapeutics’s most recent deal was a Merger/Acquisition with Transcriptx for . The deal was made on 06-Mar-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Transcriptx | 06-Mar-2020 | Merger/Acquisition | Biotechnology |
ReCode Therapeutics FAQs
-
When was ReCode Therapeutics founded?
ReCode Therapeutics was founded in 2015.
-
Where is ReCode Therapeutics headquartered?
ReCode Therapeutics is headquartered in Menlo Park, CA.
-
What is the size of ReCode Therapeutics?
ReCode Therapeutics has 105 total employees.
-
What industry is ReCode Therapeutics in?
ReCode Therapeutics’s primary industry is Drug Delivery.
-
Is ReCode Therapeutics a private or public company?
ReCode Therapeutics is a Private company.
-
What is ReCode Therapeutics’s current revenue?
The current revenue for ReCode Therapeutics is .
-
How much funding has ReCode Therapeutics raised over time?
ReCode Therapeutics has raised $388M.
-
Who are ReCode Therapeutics’s investors?
ABRDN Emerging Markets Equity Income, AJU IB Investment, Amgen Ventures, AyurMaya, and Blockchange Ventures are 5 of 23 investors who have invested in ReCode Therapeutics.
-
Who are ReCode Therapeutics’s competitors?
Regenxbio, Strand Therapeutics, ONL Therapeutics, Enterprise Therapeutics, and Aqualung Therapeutics are some of the 49 competitors of ReCode Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
